

Ref: FOI/GS/ID 5709

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

22 October 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Advanced Breast Cancer.

You asked:

- 1a. Does your trust treat advanced breast cancer?*
- 1b. If none, where are your patients referred?*
- 2. In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;*
 - HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]*
 - HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]*
 - HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]*
 - HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease*
 - Not Known*
- 3. In the past 3 months, how many breast cancer patients were treated with:*
 - Abemaciclib (Verzenio) + aromatase inhibitor **
 - Abemaciclib (Verzenio) + Fulvestrant (Faslodex)*
 - Alpelisib (Piqray) + Fulvestrant (Faslodex)*
 - Atezolizumab (Tecentriq)***
 - Bevacizumab (Avastin)*
 - Eribulin (Halaven)*
 - Everolimus (Afinitor) + Exemestane*
 - Fulvestrant (Faslodex) as a single agent*
 - Gemcitabine + paclitaxel*
 - Lapatinib (Tyverb)*
 - Neratinib (Nerlynx)*
 - Olaparib (Lynparza)*

*Palbociclib (Ibrance) + aromatase inhibitor**
Pertuzumab (Perjeta) + trastuzumab + docetaxel
*Ribociclib (Kisqali) + aromatase inhibitor**
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)
*Other active systemic anti-cancer therapy ***
**aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole*
***e.g. docetaxel, vinorelbine or capecitabine as a single agent*

Trust response:

1a. Yes

1b. Not applicable

2. Based on patients diagnosed at MTW from July - September 2019 inclusive, no patients were recorded as stage IV breast cancer.

3.

Abemaciclib (Verzenios) + aromatase inhibitor *	0
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)	1
Alpelisib (Piqray) + Fulvestrant (Faslodex)	0
Atezolizumab (Tecentriq)**	3
Bevacizumab (Avastin)	0
Eribulin (Halaven)	0
Everolimus (Afinitor) + Exemestane	1
Fulvestrant (Faslodex) as a single agent	1
Gemcitabine + paclitaxel	0
Lapatinib (Tyverb)	0
Neratinib (Nerlynx)	0
Olaparib (Lynparza)	0
Palbociclib (Ibrance) + aromatase inhibitor*	9
Pertuzumab (Perjeta) + trastuzumab + docetaxel	2
Ribociclib (Kisqali) + aromatase inhibitor*	0
Ribociclib (Kisqali) + Fulvestrant (Faslodex)	0
Talazoparib (Talzenna)	0
Trastuzumab + paclitaxel	3
Trastuzumab as a single agent	5
Trastuzumab emtansine (Kadcyla)	0
Other active systemic anti-cancer therapy **	29
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole	
**e.g. docetaxel, vinorelbine or capecitabine as a single agent	